Hutchmed says SANOVO trial shows PFS benefit with ORPATHYS+TAGRISSO in China
Hutchmed said its SANOVO trial showed a progression-free survival benefit for ORPATHYS plus TAGRISSO in treatment-naïve patients with MET-overexpressing EGFR-mutated lung cancer in China.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.